Serum erythropoietin levels in Japanese MDS patients; correlation with other hematopoietic factors
演題番号 : PS-1-92
鈴木 隆浩 （Takahiro Suzuki):1、翁 家国 （Iekuni Oh):1、大嶺 謙 （Ken Ohmine):1、上田 真寿 （Masuzu Ueda):1、森 政樹 （Masaki Mori):1,2、目黒 明子 （Akiko Meguro):1、岡塚 喜世志 （Kiyoshi Okatsuka):1、室井 一男 （Kazuo Muroi):1,2、永井 正 （Tadashi Nagai):1、小澤 敬也 （Keiya Ozawa):1
1:Division of Hematology, Jichi Medical University, Shimotsuke, Japan、2:Division of Cell Therapy, Jichi Medical University Hospital, Shimotsuke, Japan
Anemia is a major observation in myelodysplastic syndromes (MDS). Erythropoiesis stimulating agents (ESAs) are one of the treatment options to improve anemia. Although they are not available currently in Japan, NCCN guidelines recommend ESAs for lower-risk MDS patients with anemia and serum erythropoietin (EPO) levels below 500 mIU/mL. But serum EPO levels in Japanese patients have not been described enough. In this study we examined serum EPO in Japanese patients.
Patients with all classifications of MDS (FAB and WHO) were eligible. After obtaining informed consent, serum EPO levels were examined. We evaluated correlation of EPO with other hematological factors, e.g. risk categories of MDS, transfusion dependence, and blood count data.
At the time of submission, 28 patients were enrolled, and we performed interim analyses. Two patients were excluded due to renal dysfunction of grade 4. Analyses of the remaining 26 patients' data showed that serum EPO levels were significantly correlated with hemoglobin (Hb) levels (p<0.01), transfusion dependence (p<0.01), and reticulocyte counts (p<0.05). All the patients with EPO levels >500 mIU/mL had anemia with Hb levels <8.0 g/dL. Regression analysis showed that serum EPO increases gradually as Hb levels decrease and EPO exceeds 500 mIU/mL when Hb drops down below 8.7 g/dL. Risk category of MDS had no significant effects on EPO.
Our results indicate that in many transfusion-dependent patients (Hb <8.0 g/dL), EPO often exceeds 500 IU/mL.